// App-Quantinova.ai

4809 : Combination therapy targeting ribosome biogenesis and mRNA translation provides a novel and potent therapeutic approach to treat MYC-driven malignancy

Researchers

Presenter

  • Jennifer R. Devlin

Principal Investigators

  • Richard J. Rebello

  • Katherine M. Hannan

  • Carleen Cullinane

  • Denis Drygin

  • Gail P. Risbridger

  • Luc Furic

  • Ross D. Hannan

  • Richard B. Pearson

Medical Centers

  • Institute for Molecular Medicine Finland, Helsinki, Finland

  • Deakin University, Melbourne, Australia

  • John Curtain School of Medical Research, Canberra, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Pfizer Inc, San Diego, CA

Locations

  • Finland

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • PI3K/AKT

Drug/Treatment

  • CX-5461

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved